Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by U. Pluschnig
Her2 and Progesterone Receptor Status Are Not Predictive of Response to Fulvestrant Treatment
Clinical Cancer Research
Cancer Research
Oncology
Related publications
Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance Between Immuno-Histochemistry and MapQuant™ Microarray Based Assay
PLoS ONE
Multidisciplinary
Cyclin D1 Enhances the Response to Estrogen and Progesterone by Regulating Progesterone Receptor Expression
Molecular and Cellular Biology
Cell Biology
Molecular Biology
Neoadjuvant Treatment of HER2-positive Breast Cancer: Should Therapy Differ Based on Hormone Receptor Status?
Therapeutic Advances in Medical Oncology
Oncology
Androgen Receptor Status Predicts Response to Chemotherapy, Not Risk of Breast Cancer in Indian Women
World Journal of Surgical Oncology
Surgery
Oncology
Author Response To: Comment On: Meta-Analysis of the Impact of Progesterone Receptor Status on Oncological Outcomes in Oestrogen Receptor-Positive Breast Cancer
British Journal of Surgery
Surgery
All HER2-Positive Tumors Are Not Created Equal
Annals of Surgical Oncology
Oncology
Surgery
Phase II Trial of Fulvestrant With Metronomic Capecitabine for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Clinical Breast Cancer
Cancer Research
Oncology
Estrogen Receptor, Progesterone Receptor, and HER2-neu Expression in First Primary Breast Cancers and Risk of Second Primary Contralateral Breast Cancer
Breast Cancer Research and Treatment
Cancer Research
Oncology
Five Interpersonal Factors Are Predictive of the Response to Treatment of Major Depression With Antidepressants in Primary Care
Frontiers in Psychiatry
Psychiatry
Mental Health
